Apogee Therapeutics (APGE) Non-Current Deferred Tax Liability (2023)
Apogee Therapeutics (APGE) posted quarterly Non-Current Deferred Tax Liability of $574000.0 for Q4 2023.
Powered by 
Analysis
Apogee Therapeutics (APGE) Non-Current Deferred Tax Liability (2023) Analysis & Trends
Apogee Therapeutics (APGE) has reported Non-Current Deferred Tax Liability for 1 consecutive years, with $574000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Non-Current Deferred Tax Liability changed N/A year-over-year to $574000.0; the TTM figure through Dec 2023 stood at $574000.0 (changed N/A YoY), while the FY2023 annual figure was $574000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was little changed at $574000.0 in Q4 2023 per APGE's latest filing.
- Across five years, Non-Current Deferred Tax Liability topped out at $574000.0 in Q4 2023 and bottomed at $574000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Apogee Therapeutics | 10.18 Bn | 9.20 Bn | - |